Results of 2026 Annual General Meeting

30 October 2026

In accordance with Listing Rule 3.13.2 and section 251AA(2) of the *Corporations Act*, enclosed is a summary of the resolutions considered, the proxies received and the outcomes of voting for each respective resolution at the 2026 Annual General Meeting of Epiminder Limited held virtually on Friday, 30 October 2026.

All resolutions were passed and decided by poll.

ENDS

This announcement has been approved by the Company Secretary.

Investor & Media Enquiries

Gabriella Hold
The Capital Network
P: +61 2 7257 7338
E: gaby@thecapitalnetwork.com.au

Julia Maguire
The Capital Network
P: +61 2 7257 7338
E: julia@thecapitalnetwork.com.au

About Minder®

Minder® is a minimally invasive implantable continuous EEG Monitoring (iCEM®) device that provides clinicians and patients with long-term, objective data on brain electrical activity. The system continuously records bilateral subscalp EEG and transmits data via an external wearable and smartphone application to a secure cloud platform. Patients wear the device during their normal daily activities, enabling real-world monitoring over months or years.

The Minder® System was authorised by the FDA via the de novo pathway and is being used in DETECT as a marketed device in a post-market study. The UMPIRE first-in-human multicentre trial, published in Epilepsia (2025), demonstrated Minder's safety and high-quality signal acquisition across extended monitoring periods.

About Epiminder

Founded in 2017 by Professor Mark Cook together with the Bionics Institute, St Vincent's Hospital, the University of Melbourne and Cochlear Limited, Epiminder is a medical device and information solutions company focused on developing diagnostic and treatment tools for epilepsy and other seizure disorders where continuous monitoring is required. Epiminder is headquartered in Melbourne, Australia and has offices in the United States.

Epiminder Limited
Annual General Meeting
Friday, 30 October 2026
Results of Meeting

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result	If s250U applies
Resolution	**Resolution Type**	**For**	**Against**	**Proxy's Discretion**	**Abstain**	**For**	**Against**	**Abstain***	**Carried / Not Carried**	
1. Adoption of Remuneration Report	Ordinary	149,730,996 93.41%	2,326,390 1.45%	8,233,531 5.14%	108,376	157,964,527 98.55%	2,326,390 1.45%	108,376	Carried	No
2. Re-election of Robert Klupacs as Director	Ordinary	142,314,369 87.21%	11,916,973 7.30%	8,952,284 5.49%	133,476	151,266,653 92.70%	11,916,973 7.30%	133,476	Carried	N/A
3. Approval of Issue of Options to Rohan Hoare, Managing Director and Chief Executive Officer	Ordinary	151,724,989 94.65%	687,450 0.43%	7,891,138 4.92%	645,698	159,616,127 99.57%	687,450 0.43%	645,698	Carried	N/A
4. Appointment of Auditor (Ernst & Young)	Ordinary	154,115,276 94.42%	156,066 0.10%	8,952,284 5.48%	93,476	163,067,560 99.90%	156,066 0.10%	93,476	Carried	N/A
5. ASX Listing Rule 7.1A Approval of Future Issue of Securities (Additional 10% Placement Capacity) (Special Resolution)	Special	140,827,717 86.28%	13,311,795 8.16%	9,077,284 5.56%	100,306	149,905,001 91.84%	13,311,795 8.16%	100,306	Carried	N/A

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.